Skip to main content

Table 4 Treatment for SLE and PAH

From: Nailfold capillaroscopy as a risk factor for pulmonary arterial hypertension in systemic lupus erythematosus patients

 

SLE-PAH n = 21

SLE-nPAH n = 44

P-value

Corticosteroids, n (%)

17 (85)

44(100)

0.009

Antimalarial agents, n (%)

17 (85)

44(100)

0.009

Immunosuppressants, n (%)

 Azathioprine

8 (40)

25 (56.8)

0.212

 Mycophenolate

1 (5)

13 (29.5)

0.028

 Cyclophosphamide

3 (15)

25 (56.8)

0.002

 Methotrexate

11 (55)

19 (43.2)

0.380

PAH treatment

 Sildenafil, n (%)

12 (57.1)

–

 

 Bosentan, n (%)

10 (47.6)

–

 

 Cyclophosphamide IV, n (%)

10 (47.6)

–

 

 Methylprednisolone IV, n (%)

8 (38.1)

–

 

 Oral anticoagulants, n (%)

13 (65)

–

 
  1. nPAH no PAH, PAH pulmonary arterial hypertension, SLE systemic lupus erythematosus
Back to article page

Advances in Rheumatology

ISSN: 2523-3106